{"filing":{"accession_number":"0001193125-26-253851","cik":"0000818033","ticker":"HRTX","company_name":"HERON THERAPEUTICS, INC. /DE/","form":"8-K","filing_date":"2026-06-02","report_date":null,"primary_document":"hrtx-20260602.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/818033/000119312526253851/hrtx-20260602.htm"},"events":[{"id":7495,"run_id":6586,"accession_number":"0001193125-26-253851","anchor_item_number":"8.01","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.95,"summary":"This disclosure centers on an adverse court decision in patent litigation involving CINVANTI, a key product. The District Court held that Heron's asserted claims of U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid (June 1, 2026 decision), which directly threatens the company's ability to block generic competition from Azurity/Slayback. The litigation spans multiple years and involves substantial patent disputes; the adverse ruling is material to investors assessing Heron's product protection and competitive position.","company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","filing_date":"2026-06-02","submitted_at":null,"items":[{"id":3615,"accession_number":"0001193125-26-253851","item_number":"8.01","item_title":"Other Events.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.95,"reasoning":"This disclosure centers on an adverse court decision in patent litigation involving CINVANTI, a key product. The District Court held that Heron's asserted claims of U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid (June 1, 2026 decision), which directly threatens the company's ability to block generic competition from Azurity/Slayback. The litigation spans multiple years and involves substantial patent disputes; the adverse ruling is material to investors assessing Heron's product protection and competitive position.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:36:12.445047+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3615,"accession_number":"0001193125-26-253851","item_number":"8.01","item_title":"Other Events.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.95,"reasoning":"This disclosure centers on an adverse court decision in patent litigation involving CINVANTI, a key product. The District Court held that Heron's asserted claims of U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid (June 1, 2026 decision), which directly threatens the company's ability to block generic competition from Azurity/Slayback. The litigation spans multiple years and involves substantial patent disputes; the adverse ruling is material to investors assessing Heron's product protection and competitive position.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:36:12.445047+00:00","company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","filing_date":"2026-06-02"}]}